The 15th Issue · 24th March, 2024

China Development Forum 2024

The Continuous Development of China

Symposium on Promoting the 'Big Health'
(Keynote Speech One)

The China Development Forum (CDF) 2024, hosted by the Development Research Centre of the State Council (DRC) and organised by the China Development Research Foundation (CDRF), was held at Diaoyutai State Guesthouse in Beijing from 24th to 25th March 2024. The Symposium on Promoting the 'Big Health' was held on the afternoon of 24th March, chaired by Li Jianwei, Director-General of the Research Department of Social and Cultural Development, DRC. The speaker for the Keynote Speech One session was Huang Guo, the Deputy Commissioner of the National Medical Products Administration (NMPA).

Huang Guo summarized and introduced four major measures taken by the NMPA in recent years to promote the deep reform and high-quality development of China's pharmaceutical industry.

First, the continuous deepening of reform and innovation has accelerated the pace of drug evaluation and approval, achieving "the Chinese Speed". Unswervingly and continuously deepening the reform of the drug evaluation and approval system, improving the quality and efficiency of government services, and promoting the innovative

development of the industry with strict, efficient, and fair regulatory measures. For example, increasing guidance and support for the R&D of innovative medical devices, establishing four channels to accelerate market registration through the Provisions for Drug Registration, and implementing a new model of early intervention, tailored policy for each company, full-process guidance, and strict review linkage for key varieties, significantly shortening the evaluation and approval cycle.

Second, continuously improving the legal and standard system, providing Chinese wisdom for the legalization of drug regulation. Based on the Drug Administration Law and the Vaccine Administration Law, gradually perfecting the legal system composed of laws and regulations, departmental rules, normative documents, and technical guidance principles, and striving to create a fair and just legal environment.

Third, deeply participating in international cooperation, contributing "the Chinese Strength" to the international governance of drug safety. Adhering to the principles of openness, inclusiveness, cooperation, and mutual benefit, continuously deepening international cooperation and exchanges. For example, deepening cooperation with the World Health Organization, playing the role of a member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), and actively promoting the work of joining the Pharmaceutical Inspection Co-operation Scheme (PIC/S).

Fourth, strengthening the regulatory system, and exploring Chinese solutions for the long-term stability of drug safety. Actively serving major regional strategies, establishing the Yangtze River Delta and Greater Bay Area Sub-centers for the technical evaluation and inspection of drugs and medical devices, optimizing pre-process and in-process

communication guidance and related inspection and evaluation work, supporting the innovative R&D of pharmaceutical companies, closely supporting the high-quality development of the local pharmaceutical industry; establishing a special drug inspection center in Hebei, comprehensively strengthening the quality supervision of special drugs; continuously strengthening the construction of the regulatory talent team, accelerating the expansion of the national drug evaluation team; launching the China's Action Plan on Scientific Drug; promoting smart regulation, further deploying and advancing the modernization of drug regulation led by informatization, etc.

Huang Guo stated that China is the world's largest and most active pharmaceutical market and the most important pharmaceutical manufacturing country, with the most stable total volume and predictable growth. China's development needs an open world, and the world's development also relies on "the Chinese Strength". A series of measures for drug regulatory reform demonstrate China's confidence and determination to continue to advance reform, opening up, and innovative development. Confronted with the new situation and challenges brought by the rapid development of the pharmaceutical industry, the NMPA will strive to create a better business environment for companies and offer enhanced convenience to pharmaceutical companies for investment, operations and innovations.

(China Development Press　Written by: Zhao Haijuan; Reviewed by: Cui Keliang)

-Background Information-

Under the mandate 'Engaging with the world for common prosperity', China Development Forum (CDF) serves as an important platform for Chinese government to carry out candid exchanges and discussions with leaders of global businesses and international organizations as well as foreign and Chinese scholars. Initiated in 2000, CDF has made remarkable contributions for the policy exchange and international collaborations between China and the world.

-Media Liaison-

China Development Research Foundation

Guo Silu 18666028168/64255855-8014
Shi Yafan 13810361966/64255855-8223
Xia Tian 18801375838/64255855-8086
Shi Wanjing 18801090391/64255855-8090
Qiu Kaixian 18301078627/64255855-8103

CDRF 中国发展研究基金会
China Development Research Foundation

中国北京东城区安定门外大街138号
皇城国际中心A座15层

邮 编: 100011
电 话: 86-10-64255855
传 真: 86-10-64255855-8100
网 址: www.cdrf.org.cn
电 邮: cdrf@cdrf. org.cn

Floor15, Tower a, Imperial International Center, No.138
Andingmen Wai Avenue, Dongcheng District, Beijing, 100011, China

Tel: 86-10-64255855
Fax: 86-10-64255855-8100
Website: www.cdrf.org.cn
E-mail: cdrf@cdrf. org.cn